12:00 AM
 | 
Oct 22, 2007
 |  BioCentury  |  Emerging Company Profile

Stromedix: Untangling fibrosis

The biology of fibrosis and fibroblasts are well understood, and there are multiple pathways and targets known to regulate fibroblast activity. Yet there are no marketed drugs for fibrosis and relatively few in development, despite the importance of fibrosis in diseases of the liver, kidney, lung and heart, and morbidity and mortality equivalent to cancer. Stromedix Inc. hopes to change that equation.

Fibrosis is a tissue-level phenomenon resulting from the excessive activity of a form of fibroblasts called myofibroblasts. It occurs when the body tries to repair chronic tissue injury. The biology of fibrosis is the same whether the cause is viral, chemical, physical or inflammatory. Ongoing cycles of injury and repair lead to an accumulation of scar tissue and disruption of normal tissue architecture and function, followed by organ failure.

Part of the problem in figuring out how to tackle fibrosis is that it is a pathology, not a disease, and thus...

Read the full 747 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >